From xenon to argon: A more clinically accessible neuroprotectant?

Critical Care Medicine

Volumn 39, Issue 6, 2011, Pages 1589-1590

  Ezzeddine, Mustapha A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

argon; neuroprotection; stroke; xenon

Indexed keywords

ARGON; XENON;

ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG EFFICACY; EDITORIAL; IN VITRO STUDY; IN VIVO STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 79957667948     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182185705     Document Type: Editorial

References (6)

1. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30:2752-2758.
2. Jawad N, Rizvi M, Gu J, et al: Neuroprotection (and lack of neuroprotection) afforded by a series of noble gases in an in vitro model of neuronal injury. Neurosci Lett 2009; 460: 232-236.
3. Schifilliti D, Grasso G, Conti A, et al: Anaesthetic-related neuroprotection: intravenous or inhalational agents? CNS Drugs 2010; 24: 893-907.
4. Ginsberg MD: Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009; 40(Suppl 3):S111-S114.
5. Loetscher PD, Rossaint J, Rossaint R, et al: Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 2009; 13:R206.
6. Ryang Y-M, Fahlenkamp AV, Rossaint R, et al: Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats. Crit Care Med 2011; 39: 1448-1453